Triglyceride/HDL ratio as a screening tool for predicting success at reducing anti-diabetic medications following weight loss. by Shantha, Ghanshyam P. S. et al.
Triglyceride/HDL Ratio as a Screening Tool for Predicting
Success at Reducing Anti-Diabetic Medications Following
Weight Loss
Ghanshyam Palamaner Subash Shantha1,2, Anita Ashok Kumar1, Scott Kahan3,6,7, Pavan Kumar Irukulla4,
Lawrence Jay Cheskin5,7 *
1 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, 2 Department of Internal
Medicine, The Wright Center for Graduate Medical Education, Scranton, Pennsylvania, United States of America, 3 Department of Health Policy, Johns Hopkins
Bloomberg School of Public Health, Baltimore, Maryland, United States of America, 4 Department of Internal Medicine, The Wright Center for Graduate Medical
Education, Scranton, Pennsylvania, United States of America, 5 Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public
Health, Baltimore, Maryland, United States of America, 6 Department of Health Policy, George Washington University School of Public Health and Health
Services, Washington, D.C., United States of America, 7 Johns Hopkins Weight Management Center, Johns Hopkins University, Baltimore, Maryland, United
States of America
Abstract
Background and Objectives: Intentional weight loss, by reducing insulin resistance, results in both better glycemic
control and decreased need for anti-diabetic medications. However, not everyone who is successful with weight loss
is able to reduce anti-diabetic medication use. In this retrospective cohort study, we assessed the predictive accuracy
of baseline triglyceride (TGL)/HDL ratio, a marker of insulin resistance, to screen patients for success in reducing
anti-diabetic medication use with weight loss.
Methods: Case records of 121 overweight and obese attendees at two outpatient weight management centers were
analyzed. The weight loss intervention consisted of a calorie-restricted diet (~1000Kcal/day deficit), a behavior
modification plan, and a plan for increasing physical activity.
Results: Mean period of follow-up was 12.5 ± 3.5 months. By study exit, mean weight loss and mean HbA1c%
reduction were 15.4 ± 5.5 kgs and 0.5 ± 0.2% respectively. 81 (67%) in the study cohort achieved at least 1 dose
reduction of any anti-diabetic medication. Tests for predictive accuracy of baseline TGL/HDL ratio ≤ 3 to determine
success with dose reductions of anti-diabetic medications showed a sensitivity, specificity, positive predictive value,
negative predictive value, area under the curve, likelihood ratio (LR) + and LR-of 81, 83, 90, 70, 78, 4.8 and 0.2,
respectively. Reproducibility of TGL/HDL ratio was acceptable.
Conclusion: TGL/HDL ratio shows promise as an effective screening tool to determine success with dose reductions
of anti-diabetic medications. The results of our study may inform the conduct of a systematic review using data from
prior weight loss trials.
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Introduction
In the last decade, the prevalence of obesity [body mass
index (BMI; calculated as weight in kilograms divided by height
in meters-squared) ≥ 30], among adult Americans was 35%,
and is expected to increase in years to come [1]. Type 2
diabetes mellitus (DM) is an important problem among the
obese. Overweight (BMI 25–29.9), obese (BMI 30–39.9), and
extremely obese (BMI > 40) American adults had 1.59, 3.44
and 7.37 times higher odds, respectively, of diagnosed DM [2].
Obesity and DM in unison create enormous health care costs,
of which the direct and indirect costs of pharmacotherapy plays
a major role [3].
Intentional weight loss, by decreasing insulin resistance, is
associated with better glycemic control [4,5] and consequently
a decrease in the need for anti-diabetic medications [6].
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However, it is well known that not everyone who loses weight is
successful in reducing anti-diabetic medications [6]. Hence, a
clinically applicable screening tool that can predict success with
dose reductions of anti-diabetic medications would be useful,
and could help motivate patients, as well as assist practitioners
in patient counseling, and individualizing the intensity of weight
loss intervention for a given obese patient attempting weight
loss. Since insulin resistance is the central pathophysiology
behind obesity-associated diabetes, we hypothesized that a
marker of insulin resistance, measured at the onset of weight
loss efforts, might serve as a screening tool to predict success
with dose reductions of anti-diabetic medications
accompanying successful weight loss. Tryglyceride (TGL)/HDL
ratio is a known marker of insulin resistance [7]. To test this
hypothesis, we studied overweight and obese patients from 2
University-based weight management programs, analyzing the
relationship between triglyceride/HDL ratio and success in
reducing anti-diabetic medications.
Materials and Methods
Study setting and design
This retrospective cohort study was conducted in two,
University based, specialty, outpatient weight management
clinics, the Johns Hopkins Weight Management Center in
Baltimore, MD, and the George Washington Weight
Management program in Washington, DC. Institutional review
board approval was obtained from Johns Hopkins University
institutional review board for conducting the study. Informed
consent was not obtained from the participants, as the data
was analyzed anonymously per institutional review board
guidelines. Institutional review board waived the need for
written informed consent from the participants.
Case records of patients with BMI > 25 kg/m2 at the time of
enrollment into the two weight management programs during
the period March 2008 to January 2012 were assessed for
eligibility. The study cohort consisted of patients with a
diagnosis of DM at the time of enrollment who reported taking
anti-diabetic medications. Patients were excluded if they did
not have a diagnosis of DM at the time of enrollment into the
programs.
Baseline data collection
Demographic data (age, gender, race/ethnicity),
cardiovascular risk factors (smoking, diabetes, hypertension),
medication history (anti-diabetic medications, anti-hypertensive
medications, and lipid-lowering drugs), clinical parameters
(height, weight, systolic blood pressure (SBP) and diastolic
blood pressure (DBP), and laboratory parameters (fasting
glucose, HbA1c, total cholesterol, low-density lipoprotein
cholesterol (LDL), high-density lipoprotein cholesterol (HDL),
triglycerides) were collected from the study cohort. BMI was
calculated as per standard guidelines [8]. DM was identified by
physician diagnosis.
Patient follow-up and weight management intervention
details
The weight loss intervention protocols followed at the two
participating clinics were similar, and consisted of team-based,
comprehensive evaluation and treatment for weight loss. The
study participants had physician visits for follow-up twice a
month on average. The baseline visit consisted of a physician-
conducted medical history and physical examination, blood
tests (as described above), and detailed dietary, behavioral,
and exercise evaluations. Treatment was individualized, but
typically consisted of an approximately 1000 kcal/day energy-
deficit diet, often utilizing meal replacements, a behavior
modification plan, and a plan for increasing physical activity
utilizing both aerobic exercise and strength training. These
interventions with diet, physical activity and behavior
modification were similar in both participating institutions.
Depending on treatment response, the intervention was
tailored to address individual patient needs. The decision to
alter the dose of or discontinue anti-diabetic medications was
based on the clinical judgment of the treating physicians.
Factors considered in deciding on dose reductions included
magnitude of weight loss, glycemic control, hypoglycemic
symptoms, and the patient’s compliance with the weight
management protocol.
Triglyceride/HDL ratio cutoffs tested as screening tool
Triglyceride/HDL ratios of all study cohort participants at the
time of their enrollment into the weight management programs
were calculated. Cutoffs for triglyceride/HDL ratio of ≤ 2, ≤ 2.5,
≤ 3, ≤ 3.5, and ≤ 4.0 were evaluated to determine which cut-off
value yielded optimal results as a screening tool. Using these
baseline triglyceride/HDL cutoffs, each member of the study
cohort was categorized, within each cutoff category, as
successful or unsuccessful in achieving at least one dose
reduction of any anti-diabetic medication by study exit. Patients
exited the study if they achieved at least 1 dose reduction of
any of their anti-diabetic medications, or at study conclusion in
January 2012. One dose reduction was defined as any
recorded decrease in dose of anti-diabetic medication, which
included lowering the dose or completely stopping that
particular medication.
Testing reproducibility of the triglyceride/HDL ratio
Three of the authors were involved in this experiment. One of
them was an internist with 5 years’ post medical school
experience; one was a MD with 3 years’ post medical school
experience and third was a diabetes educator with 1 year post
bachelors degree experience. All three authors received a brief
20 minutes training regarding calculation of triglyceride/HDL
ratio. A computer generated random sample (n = 60) from the
study cohort was selected. First the internist calculated
baseline triglyceride/HDL ratio for this random study cohort
patients, blinded with regard to patient and medication history.
To test intra-observer correlation, the internist recalculated
baseline triglyceride/HDL ratio, for the same random sample of
study cohort participants after 1 week, blinded with regard to
earlier triglyceride/HDL ratio results, patient and medication
history. Correlation was calculated comparing the present and
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previous findings of the internist. Then, the MD calculated
baseline triglyceride/HDL ratio for the same random sample
used by the internist, blinded with regard to patient, medication
details and triglyceride/HDL ratios. Correlation was calculated
comparing the triglyceride/HDL ratios of the internist with that
of the MD. Similarly, the diabetes educator calculated
triglyceride/HDL ratio for the same random sample and
correlation was calculated comparing her findings with that of
the internist.
Statistical analysis
Data was expressed in number (%) for categorical variables,
and as mean ± standard deviation for continuous variables.
The baseline characteristics of study cohort participants who
successfully dose reduced anti-diabetic medications were
compared with the study cohort participants who were not
successful with even 1 dose reduction of any anti-diabetic
medications, using Student’s t test and chi-squared tests, as
appropriate. Similarly, these 2 groups were compared with
regard to magnitude of weight loss and HbA1C% reduction by
study exit.
Multiple linear regression analysis and multiple logistic
regression analysis were performed with magnitude of weight
loss (kg) and dose reductions of anti-diabetic medications
(coded as a dichotomous variable) as dependent variables.
Age, gender, hypertension diagnosis, smoking, lipid lowering
medication use, duration of diabetes, baseline BMI and
TGL/HDL ratio were independent variables. In addition, logistic
regression analysis assessing association between dose
reductions of anti-diabetic medications and TGL/HDL ratio was
adjusted for magnitude of weight loss.
To assess if triglyceride/HDL ratio is an effective screening
tool to predict success with dose reductions of anti-diabetic
medications, sensitivity, specificity, positive predictive value,
negative predictive value, likelihood ratio of positive test,
likelihood ratio of negative test and area under the receiver
operating characteristics curve (ROC) were calculated, using
standard methods, for the cut-off points for triglyceride/HDL
ratios [9]. Also, TGL/HDL ratio was coded as continuous
variable and AUC was computed. Kappa statistics was used to
assess intra- and inter-observer agreement in interpreting
triglyceride/HDL ratios [9]. A P-value of <0.05 was considered
statistically significant. Statistical analyses were performed
using Stata 11.0 statistical software [10].
Results
In total, 179 patient records (107 from Johns Hopkins and 72
from George Washington) were identified and reviewed. Of
these, 58 (32%) were excluded (excluded cohort) because they
did not have a diagnosis of diabetes at the time of enrollment
into the programs. The remaining 121 (68%) with a diagnosis
of diabetes formed the study cohort. All study cohort patients
were taking one or more anti-diabetic medications at the time
of enrollment. Demographic characteristics and medication
details of the study cohort and excluded cohort are shown in
Table 1. Follow-up details of the study cohort by study exit are
detailed in Table 2.
By study exit, 81 (67%) in the study cohort achieved at least
1 dose reduction of any anti-diabetic medication. The
remaining 40 (33%) in the study cohort failed to achieve even 1
dose reduction of their anti-diabetic medication; their weight
loss and HbA1c% reduction was significantly less than those in
the study cohort who did successfully dose-reduce anti-diabetic
medications (Table 2).
Baseline BMI and TGL/HDL ratio had a strong and
independent association with magnitude of weight loss and
dose reductions of anti-diabetic medications (Table 3).
Tests for TGL/HDL ratios as a screening tool to predict
success with dose reductions of anti-diabetic medications is
shown in Table 4. When TGL/HDL ratio was coded as a
continuous variable AUC was 82. Of the selected cut-off
values, TGL/HDL ratio ≤ 3 showed optimal results with a
sensitivity, specificity, positive predictive value, negative
predictive value, AUC, LR + and LR-of 81, 83, 90, 70, 78, 4.8
and 0.2 respectively (Table 4). ROC curves can be viewed in
Figure S1 and Figure S2. Further, kappa statistics for intra-
observer agreement was 0.99 and Inter-observer agreement
Table 2. Follow-up details of the study cohort.
 Study cohort Successful# Not successful* P value
Follow-up (months) 12.5 ± 3.5 13.0 ± 2.5 12.5 ± 2.5 0.511
Baseline weight (Kgs) 126.5 ± 18.2 127.1 ± 16.4 126.9 ± 19.3 0.417
Final weight (Kgs) 110.3 ± 5.9 108 ± 11.2 117 ± 5.7 0.031
Weight loss (Kgs) 15.4 ± 5.5 16.9 ± 4.7 9.2 ± 3.1 0.029
Baseline HbA1C% 8.2 ± 1.6 8.1 ± 2.3 8.0 ± 1.7 0.179
Final HbA1C% 7.7 ± 0.3 7.4 ± 0.6 7.9 ± 0.2 0.039
Change in HbA1C% 0.5 ± 0.2 0.7 ± 0.2 0.2 ± 0.1 0.035
#Study cohort participants successful with dose reductions
*. Study cohort participants not successful with dose reductions
Table 3. Factors associated with magnitude of weight loss
and success with dose reductions.
Variables
Magnitude of weight loss
(Kgs)# Dose reductions*
 ß (95% C.I) P value OR (95% C.I) P value
Age 1.57 (-0.11 – 3.11) 0.136 1.01 (0.77 – 2.32) 0.216
Gender 0.91 (-0.62 – 2.17) 0.133 1.15 (0.67 – 2.37) 0.210
Hypertension 2.45 (-0.12 – 3.16) 0.133 0.96 (0.42 – 1.92) 0.132
Smoking 1.45 (-1.50 – 3.63) 0.511 1.07 (0.66 – 2.11) 0.286
Lipid lowering
medication use
0.97 (-1.10 – 2.36) 0.162 1.13 (0.71 – 1.96) 0.149
Baseline BMI 1.53 (0.58 – 2.27) 0.033 1.47 (1.14 – 2.35) 0.031
TGL/HDL ratio 5.28 (1.51 – 8.13) 0.014 1.31 (1.03 – 2.41) 0.022
Duration of diabetes
(yrs)
1.10 (-2.74 – 3.71) 0.159 1.14 (0.68 – 2.66) 0.291
Magnitude of weight
loss (kgs)
- - 1.18 (1.09 – 1.96) 0.031
OR: Odds Ratio; β: Linear regression coefficient; C.I: confidence interval,
#multi-variate linear regression analysis
*. multi-variate logistic regression analysis
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between the internist and the MD was 0.99 and between the
internist and the diabetes educator was 0.99.
Discussion
Our study of overweight and obese adults has identified
TGL/HDL ratio as a potentially effective screening tool to
predict success with dose reductions of anti-diabetic
medications in patients who successfully lose weight.
We found, not surprisingly, that magnitude of weight loss
was an important factor determining success with dose
reductions of anti-diabetic medications (Table 2).
Mechanistically, weight loss is accompanied by decreasing
insulin resistance and hence better glycemic control [11]. This
could explain the strong and independent association of
TGL/HDL ratio, a marker of insulin resistance [7], with
magnitude of weight loss, and thus with the higher probability
Table 4. TGL/HDL ratio as a screening tool to predict
success with dose reductions.
Parameters TGL/HDL ratio
 ≤ 2.0 ≤ 2.5 ≤ 3.0 ≤ 3.5 ≤ 4.0
Sensitivity (%) 20 41 81 85 88
Specificity (%) 95 85 83 58 35
PPV 89 85 90 80 73
NPV 37 41 70 66 58
AUC 51 62 78 65 53
LR+ 4.0 2.7 4.8 2.0 1.4
LR- 0.8 0.7 0.2 0.2 0.3
Number successful 16 33 66 69 71
Total 18 39 73 86 97
Table 1. Baseline characteristics of the study cohort.
Variables Study cohort Successful# Not successful* P-value
 (n = 121) (n = 81) (n = 40)  
Age (yrs) 51.8 ± 8.9 52.7 ± 9.1 53.7 ± 9.3 0.133
Males –n (%) 67 (55) 45 (56) 22 (55) 0.668
Caucasians –n (%) 90 (74) 63 (78) 27 (68) 0.042
African Americans –n (%) 31 (26) 18 (22) 13 (32) 0.044
Current smoking –n (%) 24 (20) 16 (20) 8 (20) 0.996
Duration of diabetes (yrs) 7.5 ± 2.5 8.0 ± 2.0 7,5 ± 2.0 0.371
Mean baseline weight (Kgs) 126.5 ± 18.2 127.1 ± 16.4 126.9 ± 19.3 0.417
Mean BMI (kg/m2) 36.1 ± 6.2 36.1 ± 5.5 35.6 ± 4.7 0.226
BMI: 25-30 –n (%) 30 (25) 23 (28) 7 (18) 0.047
BMI: 31-40 –n (%) 64 (53) 51 (63) 13 (33) 0.021
BMI ≥ 41 – n (%) 27 (22) 7 (9) 20 (50) 0.017
HbA1C % 8.2 ± 1.6 8.1 ± 2.3 8.0 ± 1.7 0.179
Mean TC (mmol/l) 5.2 ± 1.3 5.2 ± 1.1 5.1 ± 1.7 0.113
Mean LDL – C (mmol/l) 4.2 ± 1.3 4.0 ± 1.4 4.1 ± 1.2 0.091
Mean HDL – C (mmol/l) 1.2 ± 0.4 1.1 ± 0.3 1.1 ± 0.4 0.216
Mean TGL (mmol/l) 1.7 ± 0.3 2.0 ± 0.5 1.9 ± 0.6 0.166
Mean TGL/HDL ratio 2.9 ± 1.2 3.1 ± 0.8 2.8 ± 1.1 0.051
HTN diagnosis –n (%) 102 (84) 69 (85) 33 (83) 0.067
MS –n (%) 68 (56) 45 (56) 23 (58) 0.116
Lipid lowering drugs –n (%) 91 (75) 64 (79) 27 (68) 0.055
Statins 91 (75) 64 (79) 27 (68) 0.055
Atorvastatin 52 (43) 27 (33) 25 (63) 0.172
Pravastatin 24 (20) 13 (16) 11 (28) 0.133
Rosuvastatin 15 (12) 8 (10) 7 (18) 0.226
Fenofibrate 7 (6) 4 (5) 3 (8) 0.417
Anti – HTN drugs –n (%) 102 (84) 69 (85) 33 (83) 0.067
Metformin-n (dose/day) 71 (1.7g) 51 (1.7g) 20 (1.7g) 0.044
Sulphonylureas-n (%) 59 (49) 40 (49) 19 (48) 0.133
Glyburide-n (dose/day) 24 (10mg) 16 (10mg) 8 (10mg) 0.091
Glipiside-n (dose/day) 21 (10mg) 12 (10mg) 9 (10mg) 0.046
Glymipride-n (dose/day) 14 (2-4 mg) 9 (2-4 mg) 5 (2-4 mg) 0.117
Sitagliptin-n (dose/day) 19 (100 mg) 11 (100 mg) 8 (100 mg) 0.061
Insulin-n (dose/day) 59 (60 U) 45 (65 U) 14 (60 U) 0.155
#Study cohort participants successful with dose reductions
*. Study cohort participants not successful with dose reductions
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of dose reductions of anti-diabetic medications that was
observed (Table 3). This reasoning comports with our rationale
for the use of TGL/HDL ratio as a screening tool to predict
success with dose reductions of anti-diabetic medications. Prior
studies have also shown TGL/HDL ratio to positively correlate
with adiposity, and its decrease proportional to magnitude of
weight loss [12,13].
Further, 75% of our patients were using lipid lowering
medications at baseline (Table 1). However, the observed
independent association of TGL/HDL ratio with dose reductions
of anti-diabetic medications even after adjusting for lipid
lowering medication use (Table 3) highlights the potential use
of TGL/HDL ratio as a screening tool to predict success with
dose reductions of anti-diabetic medications irrespective of lipid
lowering medication use.
We note that when a screening tool is assessed for its
predictive accuracy, the prevalence of the event of interest
should be taken into consideration [14]. When the prevalence
of the event of interest (dose reductions of anti-diabetic
medications) is high (67% in our study), values of sensitivity,
specificity, positive predictive value and negative predictive
value may be less useful for clinical application, since all of the
above-mentioned indicators of test accuracy vary with
prevalence. In this context, the indicators of test accuracy
which do not significantly vary with prevalence are the most
clinically relevant. LR+ and LR-do not vary with prevalence of
the disease [14]. An LR+ >1 and an LR− <1 makes a
diagnostic test clinically meaningful, while a LR+ >10 and LR−
<0.1 indicates very high accuracy [14]. In our study, among all
arbitrary TGL/HDL ratio cut-offs assessed, TGL/HDL ratio ≤ 3,
with its LR+ of 4.8 and LR-was 0.2, had the highest predictive
accuracy. Area under the ROC curve of 78% also conveys the
same meaning. Combined with its good reproducibility,
TGL/HDL ratio may well be a clinically useful screening tool for
this purpose. Interestingly, TGL/HDL ratio has been found in
other studies to be an effective tool for predicting gestational
diabetes [15], cardiovascular risk in patients with familial
hypercholestrolemia [16], atherogenic apolipoprotein B levels
[17] and as a surrogate marker in the mechanistic pathway
through which pioglitazone possibly delays coronary atheroma
progression in diabetic patients [18].
Limitations
We observed significantly greater magnitudes of weight loss
(15.4 kgs by 15 months of follow-up) compared to typical
randomized, controlled weight loss trials (RCTs) (weight loss:
4–6 kgs within 12-15 months of follow-up, SBP/DBP: 3-4/2-3
mmHg) [19,20]. It is thus possible that confounding due to
unknown factors may have played a role. Or, surveillance bias
is possible, due to the intensity of weight loss intervention
being individualized, and the decision to dose reduce being
subjective and at the discretion of the treating physicians. Also,
small sample size limited us from analyzing our research
question with individual anti-diabetic medications and individual
BMI classes. Further, convenience sampling may have led to
selection bias. Retrospective cohort design limited us to what
was recorded in patient charts; for example, we did not have
date on waist/hip ratio, which might also have relevance as a
predictor.
Conclusions
In conclusion, TGL/HDL ratio was found to show promise as
a clinically applicable screening tool. It showed moderately high
accuracy in predicting success in reducing use of anti-diabetic
medications among overweight and obese diabetics attempting
weight loss. Further, it is easy to calculate and has good
reproducibility. Before advocating widespread use, this tool
should be prospectively validated in future RCTs or clinical
settings, and evaluated in systematic reviews using data that is
available from completed RCT’s [19,20].
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